HC Wainwright Issues Positive Forecast for electroCore (NASDAQ:ECOR) Stock Price

electroCore (NASDAQ:ECOR) had its target price increased by stock analysts at HC Wainwright from $22.00 to $25.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 72.18% from the stock’s current price. HC Wainwright also issued estimates for electroCore’s Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.60) EPS, FY2026 earnings at $0.52 EPS, FY2027 earnings at $1.34 EPS and FY2028 earnings at $2.24 EPS.

electroCore Price Performance

NASDAQ:ECOR opened at $14.52 on Wednesday. The company has a market cap of $95.18 million, a P/E ratio of -7.93 and a beta of 0.57. The firm’s fifty day moving average price is $11.51 and its two-hundred day moving average price is $8.12. electroCore has a one year low of $5.25 and a one year high of $17.84.

Institutional Investors Weigh In On electroCore

Several hedge funds have recently bought and sold shares of ECOR. HighTower Advisors LLC bought a new stake in shares of electroCore during the third quarter worth approximately $255,000. Geode Capital Management LLC lifted its holdings in electroCore by 10.3% during the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock worth $458,000 after purchasing an additional 5,951 shares during the last quarter. International Assets Investment Management LLC boosted its stake in electroCore by 27.9% in the 2nd quarter. International Assets Investment Management LLC now owns 67,820 shares of the company’s stock valued at $436,000 after purchasing an additional 14,800 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in electroCore by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after purchasing an additional 2,270 shares during the period. 26.74% of the stock is currently owned by institutional investors and hedge funds.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.